Ji Degang, Hu Guangrui, Zhang Xuanhe, Yu Tianhua, Yang Jinghui
Department of Hepatobiliary Pancreatic Surgery, China-Japan Union Hospital of Jilin University Changchun 130033, Jilin, China.
Center of Physical Examination, China-Japan Union Hospital of Jilin University Changchun 130033, Jilin, China.
Am J Transl Res. 2019 Jul 15;11(7):4290-4302. eCollection 2019.
Aberrant expression of long non-coding RNA DSCAM-AS1 (Down Syndrome Cell Adhesion Molecule antisense) has been observed in several cancers. However, the expression status, biological function and underling mechanism of DSCAM-AS1 in hepatocellular carcinoma (HCC) remain unclear. The expression of DSCAM-AS1 was detected in HCC tissues and serum from both HCC patients and healthy controls. MTS, wound healing and transwell invasion assays were used to examine the effects of DSCAM-AS1 on cell proliferation, migration, and invasion in HCC cells, respectively. MicroRNAs (miRNAs) targeted DSCAM-AS1 was predicated by Starbase2.0 and identified using luciferase reporter and RNA immunoprecipitation assays. The xenograft mice were established to examine the effect DSCAM-AS1 on tumor growth . We found that DSCAM-AS1 was up-regulated in HCC tissues relative to adjacent non-tumor tissues. Serum levels of DSCAM-AS1 were higher in HCC patients than that in healthy controls. Increased DSCAM-AS1 was associated with poor prognosis. Knockdown of DSCAM-AS1 significantly inhibited HCC cell proliferation, migration and invasion. Moreover, miR-338-3p was confirmed as a direct target of DSCAM-AS1 in HCC cells. The miR-338-3p inhibitor could partially reverse the inhibitory effect of DSCAM-AS1 depletion in HCC cells. DSCAM-AS1 positively regulated CyclinD1 and smoothened (SMO) expression (two targets of miR-338-3p) in HCC cells. Moreover, tumor growth was tremendously retarded in nude mice received injection of SMCC-7721 cells transfected with sh-DSCAM-AS1. Taken together, the present work suggested that DSCAM-AS1 functioned as an oncogenic lncRNA that promoted HCC progression by sponging miR-338-3p.
在多种癌症中均观察到长链非编码RNA DSCAM-AS1(唐氏综合征细胞粘附分子反义链)的异常表达。然而,DSCAM-AS1在肝细胞癌(HCC)中的表达状态、生物学功能及潜在机制仍不清楚。检测了HCC患者和健康对照者的HCC组织及血清中DSCAM-AS1的表达。分别采用MTS、伤口愈合和Transwell侵袭实验检测DSCAM-AS1对HCC细胞增殖、迁移和侵袭的影响。通过Starbase2.0预测靶向DSCAM-AS1的微小RNA(miRNA),并采用荧光素酶报告基因和RNA免疫沉淀实验进行鉴定。建立异种移植小鼠模型以检测DSCAM-AS1对肿瘤生长的影响。我们发现,相对于癌旁非肿瘤组织,DSCAM-AS1在HCC组织中上调。HCC患者血清中DSCAM-AS1水平高于健康对照者。DSCAM-AS1表达增加与预后不良相关。敲低DSCAM-AS1可显著抑制HCC细胞的增殖、迁移和侵袭。此外,miR-338-3p被证实为HCC细胞中DSCAM-AS1的直接靶点。miR-338-3p抑制剂可部分逆转DSCAM-AS1缺失对HCC细胞的抑制作用。DSCAM-AS1在HCC细胞中正向调节细胞周期蛋白D1(CyclinD1)和平滑肌样蛋白(SMO)的表达(miR-338-3p的两个靶点)。此外,注射转染sh-DSCAM-AS1的SMCC-7721细胞的裸鼠肿瘤生长显著减缓。综上所述,本研究表明DSCAM-AS1作为一种致癌性长链非编码RNA,通过吸附miR-338-3p促进HCC进展。